FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754550313> ?p ?o ?g. }

• W2754550313 endingPage "559" @default.
• W2754550313 startingPage "549" @default.
• W2754550313 abstract "Inhibition of apoptosis signal–regulating kinase 1, a serine/threonine kinase, leads to improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis. We evaluated the safety and efficacy of selonsertib, a selective inhibitor of apoptosis signal–regulating kinase 1, alone or in combination with simtuzumab, in patients with nonalcoholic steatohepatitis and stage 2 or 3 liver fibrosis. In this multicenter phase 2 trial, 72 patients were randomized to receive 24 weeks of open‐label treatment with either 6 or 18 mg of selonsertib orally once daily with or without once‐weekly injections of 125 mg of simtuzumab or simtuzumab alone. The effect of treatment was assessed by paired pretreatment and posttreatment liver biopsies, magnetic resonance elastography, magnetic resonance imaging–estimated proton density fat fraction, quantitative collagen content, and noninvasive markers of liver injury. Due to the lack of effect of simtuzumab on histology or selonsertib pharmacokinetics, selonsertib groups with and without simtuzumab were pooled. After 24 weeks of treatment, the proportion of patients with a one or more stage reduction in fibrosis in the 18‐mg selonsertib group was 13 of 30 (43%; 95% confidence interval, 26‐63); in the 6‐mg selonsertib group, 8 of 27 (30%; 95% confidence interval, 14‐50); and in the simtuzumab‐alone group, 2 of 10 (20%; 95% confidence interval, 3‐56). Improvement in fibrosis was associated with reductions in liver stiffness on magnetic resonance elastography, collagen content and lobular inflammation on liver biopsy, as well as improvements in serum biomarkers of apoptosis and necrosis. There were no significant differences in adverse events between the treatment groups. Conclusion: These findings suggest that selonsertib may reduce liver fibrosis in patients with nonalcoholic steatohepatitis and stage 2‐3 fibrosis. (Hepatology 2018;67:549‐559)." @default.
• W2754550313 created "2017-09-25" @default.
• W2754550313 creator A5004271735 @default.
• W2754550313 creator A5012984200 @default.
• W2754550313 creator A5013219986 @default.
• W2754550313 creator A5020766248 @default.
• W2754550313 creator A5024470010 @default.
• W2754550313 creator A5027753564 @default.
• W2754550313 creator A5032695034 @default.
• W2754550313 creator A5035838376 @default.
• W2754550313 creator A5052059601 @default.
• W2754550313 creator A5060169505 @default.
• W2754550313 creator A5064179616 @default.
• W2754550313 creator A5075322332 @default.
• W2754550313 creator A5087596327 @default.
• W2754550313 creator A5088683463 @default.
• W2754550313 creator A5088845309 @default.
• W2754550313 date "2017-12-26" @default.
• W2754550313 modified "2023-10-16" @default.
• W2754550313 title "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial" @default.
• W2754550313 cites W1622799587 @default.
• W2754550313 cites W1963682935 @default.
• W2754550313 cites W1963683487 @default.
• W2754550313 cites W1964572117 @default.
• W2754550313 cites W1969268163 @default.
• W2754550313 cites W1983417944 @default.
• W2754550313 cites W1983496515 @default.
• W2754550313 cites W1998383277 @default.
• W2754550313 cites W1999950621 @default.
• W2754550313 cites W2002349285 @default.
• W2754550313 cites W2003518626 @default.
• W2754550313 cites W2022296797 @default.
• W2754550313 cites W2034580062 @default.
• W2754550313 cites W2038774859 @default.
• W2754550313 cites W2049533426 @default.
• W2754550313 cites W2059700860 @default.
• W2754550313 cites W2063437798 @default.
• W2754550313 cites W2064403130 @default.
• W2754550313 cites W2067740038 @default.
• W2754550313 cites W2072751867 @default.
• W2754550313 cites W2087010989 @default.
• W2754550313 cites W2106768039 @default.
• W2754550313 cites W2117827638 @default.
• W2754550313 cites W2123549954 @default.
• W2754550313 cites W2129275826 @default.
• W2754550313 cites W2138306815 @default.
• W2754550313 cites W2140912550 @default.
• W2754550313 cites W2204688218 @default.
• W2754550313 cites W2311884578 @default.
• W2754550313 cites W2397785404 @default.
• W2754550313 cites W2433376106 @default.
• W2754550313 cites W2520749014 @default.
• W2754550313 cites W2531775392 @default.
• W2754550313 cites W2546306361 @default.
• W2754550313 cites W2560021029 @default.
• W2754550313 cites W2580009538 @default.
• W2754550313 cites W2589734336 @default.
• W2754550313 cites W4233179469 @default.
• W2754550313 cites W4246242867 @default.
• W2754550313 cites W4249912044 @default.
• W2754550313 doi "https://doi.org/10.1002/hep.29514" @default.
• W2754550313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5814892" @default.
• W2754550313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28892558" @default.
• W2754550313 hasPublicationYear "2017" @default.
• W2754550313 type Work @default.
• W2754550313 sameAs 2754550313 @default.
• W2754550313 citedByCount "405" @default.
• W2754550313 countsByYear W27545503132017 @default.
• W2754550313 countsByYear W27545503132018 @default.
• W2754550313 countsByYear W27545503132019 @default.
• W2754550313 countsByYear W27545503132020 @default.
• W2754550313 countsByYear W27545503132021 @default.
• W2754550313 countsByYear W27545503132022 @default.
• W2754550313 countsByYear W27545503132023 @default.
• W2754550313 crossrefType "journal-article" @default.
• W2754550313 hasAuthorship W2754550313A5004271735 @default.
• W2754550313 hasAuthorship W2754550313A5012984200 @default.
• W2754550313 hasAuthorship W2754550313A5013219986 @default.
• W2754550313 hasAuthorship W2754550313A5020766248 @default.
• W2754550313 hasAuthorship W2754550313A5024470010 @default.
• W2754550313 hasAuthorship W2754550313A5027753564 @default.
• W2754550313 hasAuthorship W2754550313A5032695034 @default.
• W2754550313 hasAuthorship W2754550313A5035838376 @default.
• W2754550313 hasAuthorship W2754550313A5052059601 @default.
• W2754550313 hasAuthorship W2754550313A5060169505 @default.
• W2754550313 hasAuthorship W2754550313A5064179616 @default.
• W2754550313 hasAuthorship W2754550313A5075322332 @default.
• W2754550313 hasAuthorship W2754550313A5087596327 @default.
• W2754550313 hasAuthorship W2754550313A5088683463 @default.
• W2754550313 hasAuthorship W2754550313A5088845309 @default.
• W2754550313 hasBestOaLocation W27545503131 @default.
• W2754550313 hasConcept C126322002 @default.
• W2754550313 hasConcept C126838900 @default.
• W2754550313 hasConcept C142724271 @default.
• W2754550313 hasConcept C143753070 @default.
• W2754550313 hasConcept C2775934546 @default.
• W2754550313 hasConcept C2777690781 @default.
• W2754550313 hasConcept C2777766500 @default.

• next